This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Sept. 10, 2012 /PRNewswire/ --
Aethlon Medical, Inc. (OTCBB: AEMD), disclosed that ThisweekinMedIT.tv (TWIMIT) features an interview with Chairman and CEO,
Jim Joyce regarding the Aethlon ADAPT™ system and Hemopurifier®. The interview can be accessed on the company's website at:
Aethlon Medical also disclosed that the San Diego Business Journal (SDBJ) has published an article regarding the company's
$6.8 million contract with the Defense Advanced Research Projects Agency (DARPA) to develop selective therapeutic filtration technology that would reduce the incidence of sepsis in wounded warfighters. The SDBJ article can be accessed on the company's website at:
ThisweekinMedIT.tv is a premier medical technology source that provides the up to date news focusing on the medical and IT industries. ThisweekinMEDIT.tv (TWIMIT) finds and reports the latest answers to the healthcare and technology questions, reports on location at the most talked about events and interviews news breaking medical companies. Bringing together creditable resources onto one site, TWIMIT works around the clock "digging deeper" on topics that are important to healthcare professionals.
About Aethlon Medical, Inc.
The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome™ to target HER2+ breast cancer, and a medical device being developed under a contract with DARPA that would reduce the incidence of sepsis in combat-injured soldiers and civilians. For more information, please visit
Certain statements disclosed in the interview with ThisweekinMedIT.tv or the article published by the San Diego Business Journal may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the FDA will not approve the initiation of the company's clinical programs or provide market clearance of the company's products, future human studies whether revenue or non-revenue generating of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy, the company's ability to raise capital when needed, the company's ability to complete the development of its planned products, the company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, the ability of the company to meet the milestones contemplated in the DARPA contract, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the company's Securities and Exchange Commission filings. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.